Recondo et al. reported a patient harboring MET exon 14 skipping who experienced PD on crizotinib, and a resistance MET mutation of Y1230C was detected both in plasma and tumor tissue at the time of progression. This patient had a PR after switched to merestinib.55 These results supported that merestinib may provide a therapeutic option to patients with METex14. The first-in-human phase I study was to evaluate the safety and tolerability of merestinib including three types of tumor without NSCLC. Overall, 60 (32%) of the 186 patients enrolled in the study had a best response of SD, and recommended a dosing of merestinib at 120 mg once daily based on acceptable exposure and safety.56 A phase II study conducted by Awad et al. was to evaluate the safety and efficacy of merestinib in patients with advanced METex14 NSCLC or patients with advanced cancer with NTRK rearrangements (NCT02920996).54
Glesatinib Glesatinib (MGCD265; Mirati Therapeutics) is another orally bioavailable, type II, multi-targeted inhibitor with potential anti-tumor activity. Glesatinib binds to and inhibits the phosphorylation of several RTKs, including the MET receptor, the TEK/TIE-2 receptor, RON, SMO, and VEGFR types 1, 2, and 3. Preclinical studies showed that glesatinib resulted in a dose-dependent inhibition of cancer cell growth with an IC50 value of 80 nM on NSCLC H1299 cells.57 A patient with METex14 NSCLC showed response to glesatinib after relapsing to crizotinib, including a reduction in size of a MET Y1230H mutation-positive liver metastases and concurrent loss of detection of this mutation in plasma DNA. |
EGFR19奥西替尼六个月影像进展求助
求助一下论坛的各位朋友，我父亲6月背痛住院，检查出来肺腺癌四期，伴随骨转移和淋巴
【跨越五年】可能是最轻松治疗的肺癌
转载自：Mia和小怪兽
现在刚好距离我爸发现肺癌过去五年了，跟大部分患者比，我爸应
我父亲的情况能否免疫治疗？
父亲因胸痛检查发现鳞癌，其中含有支气管炎和慢性阻塞性肺病 我看到网上资料说 肺炎的
请教一下基测无靶、免疫高表达后面的
治疗历程
1.治疗历程中的病情描述的变化都是基于第一次，变化于前一次的。
2.检查报告
单免坚持三年多 耐药换化疗➕免疫
自21年开始查出肺鳞癌 淋巴结转移 基因检测TP S100% 单免用了信迪利 一开始效果真好
显身卡
